Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Multiple Myeloma (MM)

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Lancet Haematol

Delforge M, Patel K, Eliason L, Dhanda D, Shi L, Guo S, Marshall TS, Arnulf B, Cavo M, Nooka A, Manier S, Callander N, Giralt S, Einsele H, Ailawadhi S, Popa McKiver M, Cook M, Rodríguez-Otero P

doi: 10.1016/S2352-3026(24)00005-X

Skin Cancer

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Lancet Oncol

Bührer E, Kicinski M, Mandala M, Pe M, Long GV, Atkinson V, Blank CU, Haydon A, Dalle S, Khattak A, Carlino MS, Meshcheryakov A, Sandhu S, Puig S, Schadendorf D, Jamal R, Rutkowski P, van den Eertwegh AJM, Coens C, Grebennik D, Krepler C, Robert C, Eggermont AMM

doi: 10.1016/S1470-2045(24)00338-3

ASH 2024

Lymphoma

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

Lymphoma

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort

Eur J Cancer

Anota A, Basset M, Charton E, Bommier C, Efficace F, Dupuis J, Cottone F, Bouabdallah KK, Mollevi C, Ysebaert L, Winter A, Bijou F, Préau M, Chauchet A, Bernier A, Fornecker LM, Hafirassou H, Carras S, Lachenal F, Lionne-Huyghe P, Detourmignies L, Leyronnas C, Drénou B, Peyrou SLG, Abraham J, Monnereau A, Fouillet L, Morschhauser F, Rossi C, Belot A, Ghesquières H

doi: 10.1016/j.ejca.2024.114210

Leukemia

Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial

Blood

Efficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, Chantepie SP, Griskevicius L, Neubauer A, Audisio E, Luppi M, Fuhrmann S, Foà R, Crysandt M, Gaidano G, Vrhovac R, Venditti A, Posthuma EFM, Candoni A, Baron F, Legrand O, Mengarelli A, Fazi P, Vignetti M, Giraut A, Wijermans PW, Huls GA, Lübbert M

doi: 10.1182/blood.2023023625

Skin Cancer

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Eur J Cancer

Egeler M, Lai-Kwon J, Tissier R, Fraterman I, Kuijpers A, Van Houdt W, Wilgenhof S, Rao A, Sandhu S, Lee R, Eriksson H, van Leeuwen M, de Ligt K, van Akkooi A, van de Poll-Franse L

doi: 10.1016/j.ejca.2024.113601

Further Publications

Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments

Eur J Cancer

Notarnicola S, Zumstein L, Paparo J, Marandino L, Perrone F, Di Maio M

doi: 10.1016/j.ejca.2023.113374

Leukemia

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

Blood

Yeung DT, Shanmuganathan N, Reynolds J, Branford S, Walia M, Yong AS, Shortt J, Chee L, Viiala N, Cunningham I, Ross DM, D'Souza AB, Wright M, Harrup RA, Forsyth CJ, Filshie R, Lane SW, Browett PJ, Grove CS, Grigg AA, Hughes TP

doi: 10.1182/blood.2024024657

Leukemia

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain

Blood

van Outersterp I, Tasian SK, Reichert CE, Boeree A, de Groot-Kruseman HA, Escherich G, Boer JM, den Boer ML

doi: 10.1182/blood.2023023120

Related content

Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trial

Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): long-term, health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

ALYCANTE: Stability or improvement in health-related quality of life three months after infusion of axi-cel in patients with R/R LBCL ineligible for ASCT

Health-related quality of life profile of newly diagnosed patients with Hodgkin and non-Hodgkin lymphomas: A real-world study including 3922 patients from the French REALYSA cohort

Decitabine in Older Patients with AML: Quality of Life Results of the EORTC-GIMEMA-GMDS-SG Randomized Phase III Trial

Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy

Systematic review of adoption, reporting and impact of health-related quality of life in phase III non-inferiority trials of systemic oncology treatments

Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid Leukemia: Results from the ASCEND Study

Tyrosine kinase inhibitor response of ABL-class acute lymphoblastic leukemia: The role of kinase type and SH3 domain